Back HIV Populations Children & Adolescents

Children & Adolescents

HIV Positive Teens May Need Modified Atazanavir Dose

HIV positive adolescents taking boosted atazanavir (Reyataz) may reach higher plasma concentrations of the drug with corresponding higher bilirubin levels than adult patients, according to results from a small Spanish study published in the January 2011 Journal of Adolescent Health. These findings suggest that teens may benefit from drug level monitoring and perhaps reducing their atazanavir doses below the level recommended for adults.

Read more:

Promising Long-term Outcomes for Adolescents with Perinatal HIV Infection

Adolescents in France who acquired HIV through mother-to-child transmission during gestation or birth demonstrated relatively good outcomes, especially considering that optimal antiretroviral therapy (ART) was not yet available during their early years, researchers reported in the July 15, 2010 issue of Clinical Infectious Diseases.

Read more:

Biomarkers of Inflammation and Cardiovascular Risk in HIV Positive Children

Children with HIV have higher levels of certain biomarkers of inflammation and endothelial dysfunction compared with healthy children, as well as coagulation abnormalities associated with higher risk of cardiovascular disease, according to 2 recently published studies. These findings, suggested to one study team, suggest that efforts to control cardiovascular risk factors should start early for HIV positive children.

Read more:

Half of Children Born to HIV Positive Mothers Do Not Receive Preventive Antiretroviral Drugs

Only about half of babies born to HIV positive mothers in 4 African countries received at least a minimum preventive dose of nevirapine (Viramune) immediately after birth to reduce the risk of mother-to-child transmission, according to a study in the July 21, 2010 Journal of the American Medical Association, a special HIV/AIDS issue coinciding with the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. The World Health Organization (WHO) has released new guidelines recommending that all women with HIV should receive antiretroviral drugs to protect against HIV transmission during pregnancy, delivery, or breastfeeding, and that diagnostic testing should be expanded for infants to enable those infected to receive prompt treatment.


Read more:

IAS 2009: Lipid and Glucose Changes Related to Boosted Darunavir (Prezista) in Children and Adolescents with HIV: DELPHI Study

Ritonavir-boosted darunavir (Prezista) was effective and generally well-tolerated at week 48 among treatment-experienced children and adolescents with HIV in the DELPHI study, according to a presentation at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) last month in Cape Town, South Africa. No change was seen in glucose levels after starting the drug, and triglyceride levels decreased significantly.

Read more: